Glenmark Pharmaceuticals Limited(IN:GLENMARK)
₹2,643.00-12.45 (-0.47%)
IN:GLENMARK
Glenmark Pharmaceuticals Limited financials statements
₹2,643.00
At close:-12.45 (-0.47%)
Want to see IN:GLENMARK full AI Analyst Report?
Glenmark Pharmaceuticals Limited (GLENMARK) Ratios
5 Followers
Glenmark Pharmaceuticals Limited Ratios
IN:GLENMARK's free cash flow for Q4 2026 was ₹0.00. For the 2026 fiscal year, IN:GLENMARK's free cash flow was increased by ₹0.00 and operating cash flow was ₹0.00. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.77 | 1.56 | 1.28 | 2.10 | 1.77 |
| Quick Ratio | 1.23 | 1.01 | 0.84 | 1.64 | 1.23 |
| Cash Ratio | 0.18 | 0.29 | 0.28 | 0.23 | 0.30 |
| Solvency Ratio | 0.21 | 0.18 | -0.17 | 0.06 | 0.13 |
| Operating Cash Flow Ratio | 0.52 | -0.14 | -0.05 | 0.12 | 0.24 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -0.49 | -0.27 | 1.26 | 1.01 |
| Net Current Asset Value | ₹ 19.04B | ₹ 20.95B | ₹ 9.17B | ₹ 11.93B | ₹ 6.37B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.03 | 0.15 | 0.09 | 0.24 | 0.23 |
| Debt-to-Equity Ratio | 0.06 | 0.28 | 0.16 | 0.49 | 0.44 |
| Debt-to-Capital Ratio | 0.05 | 0.22 | 0.14 | 0.33 | 0.30 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.05 | 0.00 | 0.29 | 0.22 |
| Financial Leverage Ratio | 1.89 | 1.81 | 1.83 | 2.04 | 1.88 |
| Debt Service Coverage Ratio | 10.27 | 0.96 | -0.03 | 1.30 | 1.05 |
| Interest Coverage Ratio | 19.16 | 20.20 | 6.58 | 8.05 | 11.94 |
| Debt to Market Cap | 0.00 | 0.05 | 0.04 | 0.33 | 0.29 |
| Interest Debt Per Share | 28.43 | 94.96 | 61.91 | 175.67 | 150.96 |
| Net Debt to EBITDA | -0.21 | 0.35 | -0.23 | 2.41 | 1.33 |
| Profitability Margins | |||||
| Gross Profit Margin | 47.60% | 66.14% | 63.79% | 62.16% | 63.04% |
| EBIT Margin | 12.92% | 14.27% | 11.43% | 9.76% | 14.95% |
| EBITDA Margin | 16.29% | 16.22% | 14.47% | 12.26% | 15.54% |
| Operating Profit Margin | 23.55% | 31.31% | 26.84% | 24.12% | 28.94% |
| Pretax Profit Margin | 11.69% | 10.47% | 0.29% | 2.06% | 11.71% |
| Net Profit Margin | 8.02% | 7.84% | -11.88% | 2.55% | 7.65% |
| Continuous Operations Profit Margin | 8.02% | 7.84% | -14.48% | -0.77% | 8.08% |
| Net Income Per EBT | 68.62% | 74.83% | -4114.72% | 123.93% | 65.34% |
| EBT Per EBIT | 49.63% | 33.44% | 1.08% | 8.53% | 40.48% |
| Return on Assets (ROA) | 6.84% | 6.52% | -10.46% | 1.53% | 5.51% |
| Return on Equity (ROE) | 12.96% | 11.83% | -19.13% | 3.14% | 10.36% |
| Return on Capital Employed (ROCE) | 29.55% | 41.50% | 39.74% | 19.71% | 28.73% |
| Return on Invested Capital (ROIC) | 20.12% | 26.41% | -1770.16% | -7.07% | 18.07% |
| Return on Tangible Assets | 7.83% | 7.18% | -11.53% | 1.75% | 6.36% |
| Earnings Yield | 2.26% | 2.46% | -5.42% | 2.27% | 7.55% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.42 | 3.20 | 6.80 | 3.59 | 3.97 |
| Payables Turnover | 2.38 | 1.75 | 1.81 | 2.20 | 1.99 |
| Inventory Turnover | 2.59 | 1.38 | 1.82 | 1.86 | 1.82 |
| Fixed Asset Turnover | 3.93 | 3.46 | 3.57 | 2.76 | 2.64 |
| Asset Turnover | 0.85 | 0.83 | 0.88 | 0.60 | 0.72 |
| Working Capital Turnover Ratio | 4.12 | 5.41 | 3.50 | 2.53 | 3.65 |
| Cash Conversion Cycle | 93.83 | 170.80 | 51.82 | 132.55 | 108.94 |
| Days of Sales Outstanding | 106.68 | 114.20 | 53.64 | 101.66 | 91.99 |
| Days of Inventory Outstanding | 140.72 | 264.67 | 200.32 | 196.42 | 200.62 |
| Days of Payables Outstanding | 153.56 | 208.07 | 202.15 | 165.54 | 183.67 |
| Operating Cycle | 247.40 | 378.87 | 253.97 | 298.08 | 292.61 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 116.91 | -29.33 | -9.41 | 22.16 | 39.29 |
| Free Cash Flow Per Share | 68.80 | -55.89 | -41.25 | 0.62 | 11.29 |
| Dividend Paid and CapEx Coverage Ratio | 2.20 | -1.01 | -0.26 | 0.84 | 1.26 |
| Capital Expenditure Coverage Ratio | 2.43 | -1.10 | -0.30 | 1.03 | 1.40 |
| Operating Cash Flow Coverage Ratio | 5.56 | -0.33 | -0.22 | 0.14 | 0.28 |
| Operating Cash Flow to Sales Ratio | 0.19 | -0.06 | -0.02 | 0.05 | 0.09 |
| Free Cash Flow Yield | 3.23% | -3.70% | -4.20% | 0.13% | 2.55% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 44.17 | 40.67 | -18.46 | 44.11 | 13.25 |
| Price-to-Sales (P/S) Ratio | 3.54 | 3.19 | 2.19 | 1.12 | 1.01 |
| Price-to-Book (P/B) Ratio | 5.72 | 4.81 | 3.53 | 1.38 | 1.37 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 30.98 | -27.00 | -23.82 | 743.79 | 39.16 |
| Price-to-Operating Cash Flow Ratio | 18.23 | -51.46 | -104.44 | 20.97 | 11.25 |
| Price-to-Earnings Growth (PEG) Ratio | 1.47 | -0.26 | -0.02 | -0.37 | -4.51 |
| Enterprise Value Multiple | 21.53 | 20.00 | 14.92 | 11.59 | 7.86 |
| Enterprise Value | 595.72B | 433.55B | 272.95B | 165.61B | 150.25B |
| EV to EBITDA | 21.53 | 20.00 | 14.92 | 11.59 | 7.86 |
| EV to Sales | 3.51 | 3.24 | 2.16 | 1.42 | 1.22 |
| EV to Free Cash Flow | 30.68 | -27.49 | -23.45 | 939.42 | 47.17 |
| EV to Operating Cash Flow | 18.06 | -52.39 | -102.83 | 26.48 | 13.55 |
| Tangible Book Value Per Share | 283.69 | 261.84 | 230.82 | 263.07 | 253.46 |
| Shareholders’ Equity Per Share | 372.52 | 313.60 | 278.13 | 335.75 | 321.99 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.31 | 0.25 | 51.17 | 1.37 | 0.31 |
| Revenue Per Share | 601.81 | 473.56 | 448.15 | 413.07 | 436.03 |
| Net Income Per Share | 48.26 | 37.11 | -53.22 | 10.53 | 33.37 |
| Tax Burden | 0.69 | 0.75 | -41.15 | 1.24 | 0.65 |
| Interest Burden | 0.90 | 0.73 | 0.03 | 0.21 | 0.78 |
| Research & Development to Revenue | 0.00 | 0.07 | 0.10 | 0.11 | 0.10 |
| SG&A to Revenue | 0.24 | 0.28 | 0.23 | 0.23 | 0.20 |
| Stock-Based Compensation to Revenue | 0.00 | -0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 2.42 | -0.59 | 0.18 | 0.72 | 0.77 |
Currency in INR

